Lupus Therapeutics Market Analysis By Disease Type(Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus), By Treatment Type(Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Biologics, Antimalarial Drugs, Corticosteroids), By Route of Administration(Oral, Subcutaneous, Intravenous), By End User(Hospitals & Clinics, Diagnostic Laboratories) & Forecast
- PUBLISHED ON
- 2024-10-03
- NO OF PAGES
- 233
- CATEGORY
- Healthcare & Life Sciences
The increasing prevalence of lupus disorders across the globe is one of the most important driving factors, impelling the growth in the global lupus therapeutics market. Moreover, the growing amount of investments, intended at developing high end and technically enabled healthcare arrangement and facilities in numerous developed as well as developing nations is also projected to foster the growth and development within the global lupus therapeutics market in upcoming years. The growing number of research and drug development and drug discovery projects under taken by the market players are also affecting the growth in the global lupus therapeutics market. However, the risk of adverse side effects caused by the medications and therapeutics in the global lupus therapeutics market may limit the industry’s growth in near future.
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was stated as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). As per the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the world infecting over 409 million population reaching to more than 5.8 million deaths as of February 13, 2022. The negative impact of COVID-19 on the healthcare sector is massive and it has considerably disturbed the healthcare industries’ complete supply chain, from raw materials to manufacturing and delivery. Likewise, the COVID-19 pandemic is expected to show a positive impact on the overall growth of the lupus therapeutics market owing to the association of COVID-19 with lupus. For instance, as per an article published by the Journal of Medical Case Reports in January 2021, connotation between COVID-19 and lupus is not yet determined but it recommends that COVID-19 could be a possible agent which is accountable for producing autoantibodies and causing systemic lupus erythematosus. There has been the first case of SLE manifestation following COVID-19 of a 39-year-old male in Iran reported by the same source.
Disease Type Insights
The systemic lupus erythematosus (SLE) segment led the market for lupus therapeutics and accounted for the largest revenue share of around 30% in 2021. Systemic lupus erythematosus is the most prevalent type of lupus that causes harm to several organs across the body such as the lungs, kidney, heart, and others. Systemic lupus erythematosus causes inflammation in the skin, lungs, joints, blood cells, kidneys, etc. This condition usually goes over cycles of flare-ups (symptoms appear) and remissions (symptoms disappear).
Route of Administration Insights
On the basis of route of administration, the market is segmented into oral, subcutaneous, intravenous and others. In 2021, the oral segment ruled the market for lupus therapeutics and held the largest market share of 38%. The oral segment is made up of small molecule drugs, which are considered the mainstream treatment for Lupus, and they are also simply managed. However, the second-largest share of the market was held by the intravenous segment in the forecasted year.
Region Insights
North America market dominated the global lupus therapeutics market in terms of demand and industry share. This trend can be accredited due to the existence of high number of important industry players as well as the presence of highly sophisticated and well-trenched medical and healthcare substructure in the region. Moreover, the increasing incidence of lupus disorders and developments in the diagnosis boost the growth of the lupus therapeutics market in this region. Furthermore, estimated approvals of new drugs and strong diagnosis plans for lupus will also contribute to the growth of the market in the Americas.
However, Asia-Pacific is anticipated to grow during the forecasted period owing to number of population and growing healthcare expenditure in this region.
Key Companies Insights
The market for lupus therapeutics is moderately competitive. With the rising applications of lupus therapeutics, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the lupus therapeutics market, ultimately boosting the market growth.
• Hikma Pharmaceuticals PLC
• Lupus Therapeutics
• Dr. Reddy's Laboratories Ltd.
• GlaxoSmithKline plc
• Amgen Inc.
• Novartis AG
• Sanofi
• UCB S.A.
• ImmuPharma PLC
• Bayer AG
• Merck & Co., Inc.
• Aurinia Pharmaceuticals Inc.
• Pfizer Inc.
• ADMA Biologics, Inc.
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International Gmbh
• Other players
Some of the Recent Developments:
• In December 2020, GlaxoSmithKline plc received the U.S. Food and Drug Administration (FDA) approval for its drug BENLYSTA (belimumab) to be used along with standard therapy for treatment of adult patients with active lupus nephritis (LN), a kidney disease caused due to SLE.
• In December 2017, Immupharma plc. developed a drug Lupozor that completed the phase 3 clinical study after receiving fast-track designation from the US Food and Drug Administration.
Segments
By Disease Type
• Systemic Lupus Erythematosus (SLE)
• Cutaneous Lupus Erythematosus
• Drug-Induced Lupus Erythematosus
• Neonatal Lupus
By Treatment Type
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Biologics
• Antimalarial Drugs
• Corticosteroids
• Others
By Route of Administration
• Oral
• Subcutaneous
• Intravenous
• Others
By End User
• Hospitals & Clinics
• Diagnostic Laboratories
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
}})
Select a license type that suits your business needs
US $3499
Only Three Thousand Four Hundred Ninety Nine US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4499
Only Four Thousand Four Hundred Ninety Nine US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5499
Only Five Thousand Four Hundred Ninety Nine US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI